Endocrine Abstracts

Objective: The objective of this Phase 2 study was to evaluate the safety of relugolix when administered for 24 weeks in women with EM-associated pain. Efficacy was exploratory assessed using leuprorelin as a reference.Design: This was an open-label extension study evaluating safety of 3 doses (10 mg, 20 mg, and 40 mg) of relugolix administered orally once daily for a total of 24 weeks in women with EM-associated pain, who had participated in a preceding...